Butyrate (Sodium/Calcium Butyrate) 관련 Ulcerative Colitis (UC)
CRecent 90-day RCT (140 IBD participants) showed oral butyrate improved Crohn's symptoms and QoL. Earlier studies on butyrate enemas showed benefit in distal UC.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dbutyrate\u0026condition\u003Dibd\u002Dulcerative\u002Dcolitis';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
결론
Recent 90-day RCT (140 IBD participants) showed oral butyrate improved Crohn's symptoms and QoL. Earlier studies on butyrate enemas showed benefit in distal UC.
Key Study Findings
Randomized Controlled Trial
n=140
Double-blind
Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study …
Dose: None
vs: placebo plus conventional therapy
Outcome: clinical disease activity and fecal calprotectin
효과: None
p=0.013
대상 집단: IBD patients (60 Crohn's disease, 80 ulcerative colitis)
basic science
Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA.
Dose: Lactobacillus reuteri E9 (dose not specified)
vs: Placebo
효과: None
< 0.05
In Vitro
Sea buckthorn berries alleviate ulcerative colitis via regulating gut Faecalibaculum rodentium-mediated butyrate biosynthesis.
Dose: None
vs: DSS-induced UC mice model
Outcome: UC symptom alleviation via gut microbiota
효과: None
p<0.05
대상 집단: DSS-induced UC murine model
In Vitro
Gut microbiota-derived butyrate mediates the anticolitic effect of indigo supplementation through regulating CD4+ T cell …
Dose: None
vs: UC animal and clinical samples
Outcome: Intestinal inflammation via CD4+ T cell regulation
효과: None
None
대상 집단: UC murine model + UC patient samples
Randomized Controlled Trial
n=36
12 weeks
Double-blind
Effects of Short Chain Fatty Acid-Butyrate Supplementation on the Disease Severity, Inflammation, and Psychological Factors …
Dose: 600 mg/kg with main meal
vs: Placebo (rice starch)
Outcome: Mayo score, ESR, anxiety/depression (HADS)
효과: Mayo score -2.33 vs +0.22
p<0.001 (Mayo, dep, GHQ)
대상 집단: Active ulcerative colitis patients
In Vitro
Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro.
Dose: None
vs: LPS-stimulated RAW264.7 cells
Outcome: Macrophage polarization (M1 to M2 shift)
효과: None
None
대상 집단: RAW264.7 macrophage cell line
Key Statistics
3
연구
390
참여자
↑
Positive
C
등급
Referenced Papers
Digestive and liver …
2026
5 인용
Phytomedicine : international …
2025
17 인용
Phytomedicine : international …
2025
13 인용
Annals of medicine
2025
12 인용
iMeta
2025
10 인용
Journal of nutrition …
2025
9 인용
Molecular medicine (Cambridge, …
2025
8 인용
Nutrients
2025
7 인용
Biomarker research
2025
6 인용
Journal of proteome …
2025
5 인용
Translational research : …
2025
4 인용
Phytomedicine : international …
2025
4 인용
Frontiers in cellular …
2025
4 인용
Langenbeck's archives of …
2025
3 인용
Mediators of inflammation
2025
2 인용
Nature communications
2025
1 인용
Frontiers in bioscience …
2025
PloS one
2025
Biochimica et biophysica …
2024
90 인용
ACS nano
2024
89 인용
Lipids in health …
2024
48 인용
ACS nano
2024
38 인용
Journal of agricultural …
2024
36 인용
Gut microbes
2024
32 인용
Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.
Systematic Review
Microbiological research
2024
31 인용
Journal of agricultural …
2024
14 인용
Journal of agricultural …
2024
12 인용
Gut microbes
2024
11 인용
Poultry science
2024
9 인용
Scientific reports
2024
9 인용
Frontiers in pharmacology
2024
2 인용
Journal of animal …
2024
Nutrients
2023
162 인용
Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: a systematic review.
Systematic Review
Gut microbes
2023
30 인용
Cells
2023
18 인용
Immunological investigations
2023
13 인용
Nutrients
2023
9 인용
Lipids in health …
2023
7 인용
Journal of agricultural …
2022
202 인용
Clinical science (London, …
2022
180 인용
Microbiology spectrum
2022
146 인용
Gut microbes
2022
107 인용
Frontiers in cellular …
2022
88 인용
Gut microbes
2022
60 인용
Nutrients
2022
54 인용
Frontiers in cellular …
2022
15 인용
International journal of …
2022
10 인용
Neurogastroenterology and motility
2020
176 인용
Frontiers in immunology
2019
3034 인용
Terapevticheskii arkhiv
2019
50 인용
World journal of …
2019
45 인용
World journal of …
2018
539 인용
Current pharmaceutical design
2018
108 인용
Journal of Crohn's …
2018
91 인용
Journal of animal …
2018
15 인용
Cell host & …
2017
399 인용
Comprehensive Physiology
2017
245 인용
Journal of gastroenterology
2016
49 인용
Proceedings of the …
2014
1853 인용
Gut
2014
1657 인용
World journal of …
2014
23 인용
Gut
2013
311 인용
Clinical nutrition (Edinburgh, …
2010
177 인용
Journal of AOAC …
2004
Resistant starches.
Other
Current opinion in …
2000
28 인용
Diseases of the …
1998
26 인용
Digestive diseases and …
1997
254 인용
Bailliere's clinical gastroenterology
1997
26 인용
Diseases of the …
1995
31 인용
The Journal of …
1994
29 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 150-600 mg/day sodium or calcium butyrate
- ibdsupport:
- 300-600 mg three times daily (900-1,800 mg/day)
- butyrateenema:
- 100 mM butyrate enema for distal UC (clinical setting only)
상한량: No established upper limit for oral supplements; most studies use 600-4,000 mg/day
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | 140 |
| Lactobacillus reuteri E9 (dose not specified) | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| 600 mg/kg with main meal | 12 weeks | Positive | 36 |
| None | -- | Positive | -- |
| 5 mg/mL | -- | Positive | -- |
| None | -- | Positive | -- |
권장 복용 시간: With meals; enteric-coated formulations recommended to reach the colon
Safety & Side Effects
보고된 부작용
- ⚠ Unpleasant taste/odor (butyric acid has a strong rancid butter smell)
- ⚠ Mild GI discomfort (nausea, bloating)
- ⚠ Belching with butyric acid odor
- ⚠ Enteric-coated formulations reduce taste issues
알려진 상호작용
- ● 5-ASA medications (mesalamine) — additive anti-inflammatory effect (potentially beneficial in IBD)
- ● No significant adverse drug interactions known
일일 최대 섭취 허용량: No established upper limit for oral supplements; most studies use 600-4,000 mg/day
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does Butyrate (Sodium/Calcium Butyrate) help with Ulcerative Colitis (UC)?
Based on 3 studies with 390 participants, there is limited but promising evidence that Butyrate (Sodium/Calcium Butyrate) may support Ulcerative Colitis (UC) management. Our evidence grade is C (Some Evidence).
How much Butyrate (Sodium/Calcium Butyrate) should I take for Ulcerative Colitis (UC)?
Studies have used various dosages. A commonly studied range is 150-600 mg/day sodium or calcium butyrate. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Butyrate (Sodium/Calcium Butyrate)?
Reported side effects may include Unpleasant taste/odor (butyric acid has a strong rancid butter smell), Mild GI discomfort (nausea, bloating), Belching with butyric acid odor, Enteric-coated formulations reduce taste issues. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Butyrate (Sodium/Calcium Butyrate) and Ulcerative Colitis (UC)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 390 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: Ulcerative Colitis (UC)
Butyrate (Sodium/Calcium Butyrate) 다른 건강 상태에 대한 근거
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.